About: Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 October 2014

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в жовтні 2014 (uk) artículu científicu espublizáu n'ochobre de 2014 (ast) scientific article published on 01 October 2014 (en)
publication date	wds:Q85678153-6F9B915C-D0EF-43BA-A87E-C28D9078BF4A
publication date	2014-10-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q85678153-88965A92-F227-4657-A114-732A6639CB6B
language of work or name	English
cites work	wds:Q85678153-00BD49CD-E8A9-4D52-9D09-14F125C0E758 wds:Q85678153-05F4979D-6CA0-4647-8254-4893B0E266A3 wds:Q85678153-0620D67E-EA01-42D3-82A1-99020FDC9FAA wds:Q85678153-086D48B7-0FAB-4389-B809-4DA8D4728017 wds:Q85678153-131E2A15-3A21-40BA-A8C5-425C0E387C4A wds:Q85678153-1ABF7318-73C2-45B7-9DBC-97404585C164 wds:Q85678153-1DB72B6E-5702-44AB-A29B-CC92244EAF37 wds:Q85678153-3052AE23-65CD-490F-931C-9AAD447A2D1E wds:Q85678153-365047E1-C473-44B5-AACD-619E00190077 wds:Q85678153-37BA3846-15AA-4C44-8281-DCAE4A522A84 wds:Q85678153-3BA7BAD7-C78B-4144-A37F-DB58440A52BD wds:Q85678153-47AD62CE-EF03-4D10-A625-22E6D05F8428 wds:Q85678153-4C4EEA7A-449D-4CF7-B3F8-5066805E7634 wds:Q85678153-4DF994F2-14D7-4D97-BFD3-3FE335194798 wds:Q85678153-56BC3EB2-2E1A-486F-AF68-83A7E2B4A1B2 wds:Q85678153-6571C7BE-48E6-4F26-BF7D-5BBCED23C731 wds:Q85678153-699C0B5E-DD58-4181-A848-02D813945724 wds:Q85678153-6E76F056-5EBA-46F4-9EE3-7E3084038578 wds:Q85678153-7318C8F4-2CF1-40AE-8A78-F34BCA8DBC38 wds:Q85678153-87E9590B-4DF5-4F0A-9AAC-41FF7D914BDD wds:Q85678153-8E066F69-21B3-4B58-A856-B211E8962B78 wds:Q85678153-9E228938-2AD3-4DCF-B34B-F4EABC7CAFD3 wds:Q85678153-A77BCF50-27C1-4287-82A2-7BB458A8AFE4 wds:Q85678153-BBB2A5FA-93C2-413A-8201-9F1530421A05 wds:Q85678153-C857A8EE-27E0-49CE-A742-DCB494255132 wds:Q85678153-D04957C0-6817-44B8-89F7-C5E29167C8D3 wds:Q85678153-D1A2737C-7196-4C6B-A96C-F46C7F3872BC
cites work	Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy Molecular genetics of the LDL receptor gene in familial hypercholesterolemia Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy A 52-week placebo-controlled trial of evolocumab in hyperlipidemia Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome Lipoprotein(a) in homozygous familial hypercholesterolemia Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment Recommendations for the use of LDL apheresis The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials
author name string	wds:Q85678153-055552AB-AD56-4AFB-B0DE-9D3D0422B29F wds:Q85678153-11A1730C-32BF-49FC-B29D-DB01EEF7AF06 wds:Q85678153-2D009582-B682-44AC-98A3-5A3DDC11809D wds:Q85678153-656B4DB3-DFBB-43FD-89D6-2B7B67B6816B wds:Q85678153-747FE9B5-2148-4C2F-89BC-557931579E5B wds:Q85678153-9AAEDF50-4C0E-4156-AADA-E5AFFD5C33C1 wds:Q85678153-EA13E65A-3A66-4171-831B-E4B9857AF930 wds:Q85678153-F3629CDC-112B-4F01-AB14-B9D29F408A36
author name string	Scott M Wasserman Feng Xu G Kees Hovingh Evan A Stein Frederick J Raal Dirk J Blom Narimon Honarpour TESLA Investigators
rdfs:label	Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial (en) Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial (nl)
skos:prefLabel	Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial (en) Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial (nl)
name	Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial (en) Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial (nl)
author	wds:Q85678153-94973F15-40FD-47B7-92D3-7DC6EE3130F1
author	Robert Scott
title	wds:Q85678153-C2515561-F034-4014-9189-87B70BBE9587
title	Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial (en)
page(s)	wds:Q85678153-163042F6-0B3C-4B12-A2EA-5F3B9663CBB3
page(s)	341-350
instance of	wds:Q85678153-8C667DE9-EFA8-483A-9959-4E28071AC73A
instance of	scholarly article
main subject	wds:Q85678153-6BD4905C-138B-4972-A9B9-B0B365A4AE64 wds:Q85678153-EFF88657-5BA4-46B2-9C0B-B530F45FB8AD wds:Q85678153-F14BD58E-2C05-499B-B18E-F07E31BCA1A0
main subject	placebo placebo-controlled trial homozygosity
PubMed ID	wds:Q85678153-F7FCD046-3202-48C1-AE92-1267C5F645DB

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software